

**Notice of References Cited**

Application/Control No.

09/546,573

Applicant(s)/Patent Under

Reexamination

HOLTEN-ANDERSEN ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 1 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
	A	US-5,356,817-A	10-1994	Cole, LA	436	64
	B	US-				
	C	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	H	US-				
	I	US-				
	J	US-				
	K	US-				
	L	US-				
	M	US-				

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Oberg, A, et al, 2000, Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer, Anticancer Research, vol. 20, No. 2B, pp. 1085-1091.
	V	Holten-Andersen, MN, et al, 2000, High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, Clinical Cancer Research, Vol. 6, No. 11, pp. 4292-4299.
	W	Michael, M, et al, 1999, Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer, Journal of Clinical Oncology, Vol. 17, No. 6, pp. 1802-1808.
	X	Pohl, AL, et al, 1994, Neural network evaluation of multiple tumor markers for diagnosis of ovarian cancer (meeting abstract), Non-serial, 3 <sup>rd</sup> International Conference of the Mediterranean Society of Tumor Marker Oncology, CANCERLIT Accession No. 95614997.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

*J Rawlings*  
SR 8/25/01

**Notice of References Cited**

Application/Control No.

09/546,573

Applicant(s)/Patent Under

Reexamination

HOLTEN-ANDERSEN ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 2 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ward, AM, 1985, Tumour Markers, Developmental Oncology, Vol. 21, pp. 90-106.
	V	Genesis Group Associates, Inc., 1997, New tests improve breast cancer prognosis, Genesis Report-Dx, Vol. 6, No. 3, NLDB Accession No. 97:320100.
	W	Berend, KR, et al, 1998, Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival, Journal of Bone and Joint Surgery, American Volume, Vol. 80, No. 1, pp. 11-17.
	X	Ikebe, T, et al, 1999, Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer, Clinical and Experimental Metastasis, Vol. 17, No. 4, p. 315-323.

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No.	Applicant(s)/Patent Under Reexamination	
	09/546,573	HOLTEN-ANDERSEN ET AL.	
Examiner	Stephen L. Rawlings, Ph.D.	Art Unit	Page 3 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Arnold, SM, et al, 1999, Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in paired primary tumors and brain metastases, Clinical Cancer Research, Vol. 5, No. 12, pp. 4028-4033.
	V	McKay, JA, et al, 2000, Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas, International Journal of Oncology, Vol. 17, No. 1, pp. 153-158.
	W	Aoudjit, F, et al, 1999, Gelatinase B (MMP_9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma, International Journal of Cancer, Vol. 82, No. 5, pp. 743-747.
	X	Zhou, W, et al, 1998, Identifying markers for pancreatic cancer by gene expression analysis, Cancer Epidemiology, Biomarkers and Prevention, Vol. 7, No. 2, pp. 109-112.

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No.	Applicant(s)/Patent Under Reexamination	
	09/546,573	HOLTEN-ANDERSEN ET AL.	
Examiner	Stephen L. Rawlings, Ph.D.	Art Unit	1642

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Tockman, MS, et al, 1992, Considerations in bringing a cancer biomarker to clinical application, Cancer Research, Vol. 52, Suppl., pp. 2711s-2718s.
	V	
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

8/25/01